Reimagining pharma brand tracking: How human-guided AI is helping ATUs explain behaviour, not just measure it

Executive summary: This blog post explores how human-guided AI is reshaping pharma brand tracking by helping teams understand not just what changed, but why. It highlights two practical applications - AI-enabled qualitative moderation and conversational probing within quantitative surveys - that, when combined with expert oversight and robust governance, enable richer, more actionable insights into the drivers of awareness, trial, and usage. By moving beyond measurement to explain behaviour, AI can help transform ATU programmes into more responsive learning systems that support faster, more confident decision-making.

Pharma brand trackers have always been good at telling us what is changing in the market. The harder question is why.

That’s where AI, when used thoughtfully, can make a meaningful difference.

At Escalent Group, we believe AI creates the most value when it is human-guided, expert-led, and used within a governance structure. In healthcare and life sciences, that matters. Tracking programmes inform important decisions, so the goal is not to hand research over to AI entirely. It is to use carefully vetted AI tools to help teams learn faster, probe deeper, and act with greater confidence.

Used in that way, AI can help Awareness, Trial and Usage (ATU) studies do something they have long struggled with: explain behaviour, not just measure it.

Awareness rises, but trial does not follow. Consideration softens, but the reason is unclear. Usage stalls, yet the topline alone cannot tell you whether the friction is clinical confidence, patient fit, access, administration, or simple inertia.

ATUs remain essential. They give brands a consistent read on awareness, uptake, perceptions, and movement over time. But in today’s market, they are being asked to do more than they were originally designed for. Commercial and insights teams do not just want to know what changed. They need to understand what is driving that change, where behaviour is stalling, and what action to take next.

In practice, we are seeing two AI-enabled applications make that shift possible.

1. Human-guided AI moderation is bringing richer learning into every brand tracking wave

Qualitative research has always helped explain the story behind the numbers. The challenge is that, within most tracking programmes, it is constrained by time and budget. A team may only be able to run a small number of interviews, which means qualitative often ends up as occasional depth rather than a consistent input into learning.

AI-enabled moderation changes that.

By using AI to moderate interviews, we can conduct far more conversations than would typically be possible within standard client budgets, and we can do so quickly enough for the insights to feed directly into the tracking readout.

AI-enabled interviews also make it easier to run multilingual research within a single wave. For example, a US tracker running in English and Spanish can now capture consistent qualitative input from Spanish-speaking respondents at scale, without requiring separate translation workflows.

But the value does not come from scale alone. It comes from combining that scale with expert oversight. Researchers still shape the discussion guide, define the learning objectives, review the inputs, and interpret the outputs. AI helps scale and accelerate the conversations; human experts ensure the outputs are meaningful, relevant and correctly interpreted.

That shifts the role of qualitative in a tracking programme.

Instead of sitting outside the tracker as an occasional add-on, it becomes part of the regular rhythm. For each wave, teams can focus on the topics that matter most: reaction to new data, barriers to switching, confidence in a brand message, perceptions of patient fit, or evolving concerns around access and affordability.

Because the interviews can be conducted at greater scale and speed, those questions can be explored in time to shape the next readout.

The benefit is not just efficiency. It is explanation.

If consideration declines, the team is not left guessing. If usage remains flat despite stronger awareness, the tracker can surface what respondents are actually wrestling with. If one audience segment is moving differently from another, the qualitative layer helps explain why.

There is also an important advantage in breadth. More interviews mean more voices, more variation in experience, and more confidence that the themes emerging in the reporting reflect the market, not just a narrow slice of it.

The result is a richer tracking programme that can deliver ongoing qualitative depth alongside quantitative measurement, rather than relying on separate qualitative studies to fill in the gaps. In one quarterly tracking programme, this approach allowed the team to explore a new wave-specific question on switching barriers and bring that learning into the scheduled readout, rather than waiting for a separate qualitative study.

2. How AI-enabled probing inside quant surveys is turning open ends into real conversations

The second application sits within the survey itself.

Traditional open-ended questions in quantitative research have always had value, but they come with a clear limitation. Respondents often provide a short answer, and the survey moves on. You get a comment, but not necessarily the thinking behind it.

AI-enabled conversational agents change that by allowing the survey to probe intelligently based on what the respondent has actually said.

Instead of asking a single open-ended question and stopping there, the survey can follow up with prompts that adapt to the respondent’s answer. A one-line response becomes a short but meaningful exchange.

For pharma research, that is a meaningful step forward.

A healthcare professional might say they are hesitant to use a therapy because it feels “difficult.” In a traditional survey, that might be where the insight ends. With AI-enabled probing, the survey can ask what “difficult” means in practice. Is it reimbursement uncertainty? Administrative burden? Patient selection? Monitoring requirements? Concerns around tolerability? A lack of confidence in the evidence package?

That is a very different level of learning.

Here too, the value depends on guardrails. The probing should sit within clear research objectives, agreed topic boundaries, and approved prompting logic, with human review of what emerges. That keeps the conversation relevant, appropriate, and useful to the business question at hand.

AI-enabled probing helps uncover the motivations, barriers, and triggers sitting underneath behaviour. It reveals why respondents stall at a given point, whether that is awareness, consideration, trial, or more sustained usage.

And that context matters.

Rather than simply reporting that a KPI moved, teams can understand the forces behind the movement. They can see what is preventing forward momentum, what is fuelling hesitation, and where activation strategies need to work harder.

The outcome is not just better verbatims. It is better diagnosis.

And better diagnosis leads to better decisions.

Introducing AI into pharma brand tracking and ATU studies: Where to start

For teams considering AI in ATUs, the best place to start is not with a platform demo. It is with a recurring question that the tracker still struggles to answer.

Maybe awareness is moving but trial is stalling. Maybe switching intent looks promising, but behaviour is not following. Maybe open ends suggest a problem, but lack sufficient detail to guide action.

Start there.

If the challenge is depth and context, AI-enabled qualitative may be the better first step. If the challenge is getting more meaning from moments already built into the survey, AI-enabled probing inside quant can create value faster.

Once the objective is clear, thoughtful governance becomes the essential next step. Define who shapes the guide or prompting logic, who reviews the outputs, how quality is checked, and what success looks like. The strongest AI-enabled programmes are not the ones using the most technology. They are the ones using it most deliberately.

Pharma brand tracking’s evolution from scorecards to learning systems

Taken together, these applications point to a bigger shift.

The most effective tracking programmes are no longer just periodic scorecards. They are becoming more responsive learning systems, designed to explain change, not just measure it.

That is the real value of AI in ATUs.

Not more technology for its own sake. Not more jargon layered onto familiar methods. But a practical way to build more depth, flexibility, and relevance into the research teams already trust.

When applied well, AI can help close one of the oldest gaps in tracking research: the gap between seeing movement and understanding it.

For pharma teams, that is a meaningful advantage.

Because the future of brand tracking will not belong to programmes that simply report what changed. It will belong to programmes that can explain why it changed, what it means, and where teams should act next.

To discuss how human-guided AI could enhance your ATU or brand tracking programme, get in touch.

Meet our authors

Matt Turner, Group Strategy Director, Hall & Partners
Jessica Erley, Vice President, Escalent